Magnesium: Why you need this mineral for better sleep, mood and more – CNET

Getty Images

Most of us have a cabinet full of supplements that at some point, get neglected. Whether it's because you fell out of your routine or you forgot why you even started it in the first place, there's one that most Americans could benefit from adding back into their regimen: magnesium.

Studies show that the majority of the population is at risk for magnesium deficiency due to a variety of lifestyle factors, including a diet high in processed food. Certain illnesses or health conditions, including Type 2 diabetes or alcohol dependency, can make you susceptible to low magnesium levels, too. A 2013-2016 analysis from the National Health and Nutrition Examination Survey found that 48% of Americans don't get adequate magnesium in their diets.

Our Health & Wellness newsletter puts the best products, updates and advice in your inbox.

Magnesium supplements have become popular in the wellness space recently, and many experts are recommending them for helping with sleep, stress, anxiety and more. But do these claims hold up? Below, I give an overview of the science on magnesium, and I also talked to registered dietitian Amy Gorin to find out more on why magnesium is important and how to know if a supplement may be right for you.

Magnesium requirements vary based on a person's age, gender and other health factors (like pregnancy), but the average recommendation is around 300mg per day.

"Magnesium is important for so many aspects of health. The mineral is involved in more than 300 enzymatic reactions in the body. It's important for bone health, helping to keep your blood sugar levels stable, helping your muscles and nerves to properly function, and keeping your blood pressure at healthy levels," Gorin says.

Magnesium levels also affect your brain and your mood, which is why low levels of magnesium are associated with mood disorders, although more research needs to be done to determine just how important it is for your emotional or mental health.

If you've ever asked a health expert about the best supplements for stress, chances are magnesium is on the list. Why? First of all, according to Gorin, magnesium helps the brain cope with stressors. "Research has shown that magnesium supplementation may affect the brain functions that help lower stress and anxiety," Gorin says.

It works by helping your body kick into the "rest and digest" state, or by activating your parasympathetic nervous system. When you are stressed, your body is likely in the sympathetic nervous system for prolonged periods, which over time can make you feel run down and tired. Studies also showed that magnesium intake helped improve heart-rate variability (HRV) scores, which are representative of how well your body can adapt to stress.

Likewise, magnesium can help you sleep better, since the mineral can have a calming effect on your body. Magnesium helps regulatethe hormone melatonin, which is involved with controlling your circadian rhythm. Your circadian rhythm regulates many things in your body, including when you feel tired and how well you sleep.

Many activities and habits can throw off your circadian rhythm, including exposing your eyes to blue light at night. If you are trying to optimize your circadian rhythm, or are trying to get better sleep with melatonin supplements, you should check that your magnesium levels are optimal since they work together to help you get better rest.

A 2017 study reviewed the connection between magnesium and exercise performance, and found that the more active you are, the more your body needs magnesium. Some claim that it can help you recover faster from workouts, but the evidence on magnesium specifically for workout recovery is limited.

We do know that your muscles need adequate magnesium to function well and avoid cramping, so it makes sense that optimal magnesium levels can facilitate better recovery from workouts.

Grains and seeds contain naturally occurring magnesium.

Vitamin D is crucial for your overall well-being and especially for your immune system health. But even if you think you're getting enough vitamin D through supplementation or sun exposure, you could still be low if your magnesium levels are not optimal.

According to the American Osteopathic Association, low magnesium levels can make vitamin D ineffective. That means that even though you are taking in vitamin D from food, supplements or sunlight exposure, your body can't use it or benefit from it unless you have sufficient magnesium levels.

Magnesium is found naturally in food, like leafy vegetables, whole grains, nuts, seeds and milk, but it's usually in smaller amounts and it can be difficult to get the full 300 mg or more that is needed per day. Plus, scientistspredict that only about 30% to 50% of the magnesium that you take in is actually absorbed in the body. For these reasons, many people turn to a supplement to ensure they are meeting their daily needs.

There are several different types of magnesium supplements that can help specific issues.

If you walk into a vitamin or health food store and look for magnesium supplements, you will likely find several different types. You can get magnesium supplements in powder form (like the popular Natural Vitality Calm supplement) that can be dissolved in water or you can take the mineral in a capsule or tablet.

But not all magnesium supplements are the same, which is why it's important to not only seek a health professional's guidance on which supplement may be best for you, but also understand that different forms of magnesium can have different side effects. For example, magnesium carbonate is one form of magnesium that, if you overdo it, you can end up with stomach upset and diarrhea.

Popular forms of magnesium that are available in supplements:

Magnesium glycinate:"This is a common form of magnesium in supplement form. You might also see it used in heartburn treatments," Gorin says. Magnesium glycinate is often recommended by experts since it's absorbed well in the body and tends to cause less stomach discomfort or upset.

Magnesium oxide: "This form of magnesium can be used as an antacid for heartburn relief, as a short-term laxative, or as a dietary supplement when you're not taking in enough magnesium from food," Gorin says.

Magnesium citrate: "This form of magnesium is sometimes used as a stool softener or laxative," Gorin says.

Magnesium L-threonate:"This is a specific type of magnesium that's been proven to have cognitive benefits. It was discovered by MIT researchers, and you can get it in supplement form. Research suggests that it may help improve brain plasticity, which may have positive effects on memory, learning and cognition," Gorin says.

Now playing: Watch this: Telehealth will be the new normal after the pandemic

26:07

The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.

Read the original here:

Magnesium: Why you need this mineral for better sleep, mood and more - CNET

Global Amaranth Oil Market (Impact Of COVID-19) Growth, Overview With Detailed Analysis 2020-2025 – Counter Current

Global Amaranth Oil Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 launched by MarketsandResearch.biz aims to unveil key opportunities available in the global market to help players in securing a strong market position in the market. The report provides a detailed analysis of the market status, investment plans, production and consumption, price trends, and analysis by the market player, by region, by type, by the application. The report comprises verified and reliable market forecasts for the overall size of the global Amaranth Oil market in terms of revenue. The report discusses all major market aspects with an expert opinion on current market status along with historic data. A comprehensive analysis of the market standard, geographical regions, market key vendors, end-user applications, and products are studied in this study report.

The report embodies market outlook, modern-day methods, institution, size, revenue, and trends of the global Amaranth Oil market from 2020-2025. The report discloses various opportunities, growth and restraining factors, and challenges faced by major market players. Further, all the major probabilities relevant to market circumstances are showcased by clearly explaining segmentation analysis. The geographical research provides accurate value and volume forecasts, thereby helping market players gain profound insights into the market.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/13190

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Top Players:

Competitors analysis includes market shares for all the companies listed below, competitors analysis revenue chart, competitive dashboard, and the competitors latest strategies. Market top players can utilize this analysis to increase the upper hand over their rivals in the market. Along with, the rise and falls that resist the global Amaranth Oil market major contribution towards the rising of the key players in the leading market is discussed.

Influential players covered up in the report: Amr Amaranth, Amaranth Bio, Amaranth Nord, Proderna Biotech, Flavex Naturextracte, Nu-World Foods, Saar, Nans Products, Flaveko Trade Spol, Dk Mass, Rusoliva,

By type, the market is segmented into: Cold Pressed, Supercritical CO2 Extraction, Organic Solvent (Hexane) Extraction, Others

By application, the market is segmented into: Cosmetic & Personal Care, Pharmaceutical, Food Supplements, Others

The analysis can be also bifurcated industry around the grounds of locations North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) to test the development pattern of this market at numerous geographic locations.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/13190/global-amaranth-oil-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Reasons For Buying This Report:

Moreover, the report gives production, consumption, sales, and other market forecasts. The document contains the details associate with sales channels, suppliers, traders, dealers, research findings and conclusion, etc for the Amaranth Oil market. In-depth global market progress and outlook linked with the factors boosting the market are explained in the report.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

See more here:

Global Amaranth Oil Market (Impact Of COVID-19) Growth, Overview With Detailed Analysis 2020-2025 - Counter Current

Pennsylvania Mesothelioma Victims Center Urges the Family of a Person with Recently Diagnosed Mesothelioma in Pennsylvania to Please Call Attorney…

(MENAFN - EIN Presswire)

PITTSBURGH , PENNSYLVANIA , USA, August 3, 2020 / EINPresswire.com / -- The Pennsylvania Mesothelioma Victims Center says, "We are urging the wife or adult son-daughter of a person who has just been diagnosed with mesothelioma anywhere in Pennsylvania to insist on much better financial compensation results and to call attorney Erik Karst of the law firm of Karst von Oiste at 800-714-0303 to get the job done. To get the best possible mesothelioma compensation it is vital a person with mesothelioma hire lawyers that know what they are doing. Erik Karst is one of the nation's leading mesothelioma lawyers and he will know how to help a person with this rare cancer caused by asbestos exposure in Pennsylvania.

"Because Pennsylvania was hit hard by the Coronavirus there is a good chance a person with mesothelioma was initially diagnosed this virus. If and when-the doctors figured out that the person had mesothelioma as opposed to the Coronovirus a couple of months were lost as far as proper treatment.

"If this sounds like you or your loved one and the mesothelioma has been confirmed please call attorney Erik Karst of the law firm of Karst von Oiste at 800-714-0303 to get the compensation process moving. Erik and his colleagues at Karst von Oiste have been assisting people with mesothelioma for decades and they are responsible for over a billion dollars in financial compensation for people like this. The average age of a person with mesothelioma is about 72 years old. Please don't roll the dice on mesothelioma compensation." [To enable links contact MENAFN]

The Pennsylvania Mesothelioma Victims Center wants to emphasize their services for a person with mesothelioma or asbestos exposure lung cancer are available throughout the state of Pennsylvania including communities such as Philadelphia, Pittsburgh, Allentown, Eire, Upper Darby, Reading, Scranton, or Bethlehem.

[To enable links contact MENAFN]

For the best possible treatment options in Pennsylvania we strongly recommend the following two heath care facilities with the offer to help a diagnosed victim, or their family get to the right physicians at each hospital.

* Penn's Abramson Cancer Center in Philadelphia: [To enable links contact MENAFN] .

* University of Pittsburgh Cancer Institute: [To enable links contact MENAFN]

High risk work groups for exposure to asbestos in Pennsylvania include US Navy Veterans, power plant workers, shipyard workers, oil refinery workers, steel mill workers, coal miners, manufacturing workers, plumbers, electricians, welders, pipefitters, insulators, boiler technicians, auto mechanics, machinists, or construction workers. Typically, the person's exposure to asbestos occurred in the 1950's, 1960's, 1970's, or 1980's. [To enable links contact MENAFN]

According to the CDC the states indicated with the highest incidence of mesothelioma include Maine, Massachusetts, Connecticut, Maryland, California, New Jersey, Pennsylvania, Ohio, West Virginia, Virginia, Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon. [To enable links contact MENAFN]

For more information about mesothelioma please refer to the National Institutes of Health's web site related to this rare form of cancer: [To enable links contact MENAFN]

Michael ThomasPennsylvania Mesothelioma Victims Center+1 800-714-0303email us here

Read more from the original source:

Pennsylvania Mesothelioma Victims Center Urges the Family of a Person with Recently Diagnosed Mesothelioma in Pennsylvania to Please Call Attorney...

Asbestos-Related Lung Cancer: Prevention and Awareness – Asbestos.com

Aug. 1 is World Lung Cancer Day, and the American Lung Association is encouraging everyone to educate themselves on environmental risk factors and prevention through early screening.

Lung cancer can affect anyone, and it remains the most common and deadly cancer worldwide. The disease is responsible for approximately one in five deaths globally and accounts for over 2 million cases annually.

Taking steps to avoid exposure to dangerous substances and environmental toxins can substantially decrease the risk of developing lung cancer and other diseases such as mesothelioma.

Smoking causes an overwhelming 80% of lung cancer deaths, but it is essential to recognize other risk factors. Many people diagnosed with the disease never smoked in their lives. Exposure to toxins such as asbestos increases the risk of lung cancer in smokers and non-smokers.

Inhaling asbestos dust causes microscopic fibers to become trapped within the lung tissue. Over several years, asbestos in the lungs causes damage to DNA that results in mutations that produce lung cancer. More commonly, asbestos becomes lodged in the lining surrounding the lungs, causing pleural mesothelioma.

Similar to mesothelioma, asbestos-related lung cancer usually develops around 15 to 35 years after initial exposure. Physicians diagnose most cases in workers who experienced occupational exposure after working with asbestos decades prior.

Lung cancer prevention starts with identifying if you are part of a population at risk for developing the disease. Many employers knowingly exposed their workers to asbestos for decades before regulation became widespread.

Workers in the mining, construction, shipbuilding and firefighting industries are most at risk due to the historical use of asbestos materials in structures and manufacturing. Veterans are also at high risk because of the militarys use of the substance in older bases and ships.

Adults over the age of 55 who are smokers or at risk of asbestos-related lung cancer can take significant preventative measures by undergoing screening.

A new low-dose CT scan is now available, and the Centers for Disease Control and Prevention recommends the scan for older adults with a history of smoking. However, those with a history of possible asbestos exposure should also talk to their doctors about undergoing a low-dose CT.

If more Americans adopt preventative measures against lung cancer, early screening can significantly improve lung cancer survival rates. The American Lung Association estimates low-dose CT scans could save 25,000 lives every year if the 8 million high-risk Americans underwent early screening.

Discussing a potential history of asbestos exposure with your primary care physician is the first step in getting the recommended tests and an accurate diagnosis.

In addition to asbestos exposure, genetics and overall health play a role in the development of lung cancer. Identifying just one risk factor, such as occupational asbestos exposure, can prevent years of lung cancer treatment.

Patients with lung cancer typically experience shortness of breath, chest pain and general fatigue. Symptoms usually only arise once lung cancer has entered its later stages. At that time, lung cancer is more challenging to treat and options are limited.

The CDC recommends people with a history of asbestos exposure seek regular screening for asbestos-related lung cancer. However, there are other environmental sources of lung cancer that might not be common knowledge.

Asbestos-related lung cancer accounts for approximately 4% of all lung cancer deaths. Many Americans may not realize the risk of asbestos in homes. Houses and buildings built before the 1980s are likely to contain asbestos in the insulation, flooring, roofing or other construction materials.

When asbestos-containing materials are damaged, the fibers escape as microscopic particles that pollute the air. Owners of older homes should be aware of asbestos-containing materials used in their houses.

The second-most common cause of lung cancer is also present within the home. Radon is a colorless and odorless gas that is radioactive. It is found in homes and commercial buildings across the U.S. The gas forms naturally in the ground after the radioactive decay of soil and rock.

Radioactive radon particles can become lodged in the lungs and damage cellular tissue, eventually causing cancer. Radon is responsible for approximately 20,000 lung cancer deaths annually, and smokers exposed to radon have a higher risk of developing lung cancer.

The Environmental Protection Agency estimates that one in 15 homes in America has elevated levels of radon gas. Testing for the gas is easily accessible through self-testing kits and recommended for homes with or without basements. Addressing elevated levels of radon can prevent lung cancer for everyone in the household.

Other lesser-known environmental causes of lung cancer include outdoor air pollution, such as engine exhaust, and silica dust resulting from the breakdown of construction materials.

While the dangers of asbestos and smoking are well known, many other factors could put you at a higher risk for lung cancer.

For World Lung Cancer Day, take time to educate yourself and others on simple measures you can take to prevent this deadly illness. Talk to your physician about your familys history of cancer, and test your home for asbestos or radon. Its never too early to start preventative measures that could one day save your life.

Free Mesothelioma ResourcesGet Access to Free Resources for Patients & Loved Ones

Read the original here:

Asbestos-Related Lung Cancer: Prevention and Awareness - Asbestos.com

Mesothelioma Treatment Market Sales, Price, Revenue, Gross Margin and Industry Share 2020 2027 – Owned

The Mesothelioma Treatment Market research report thoroughly explains each and every aspect related to the Global Mesothelioma Treatment Market, which facilitates the reports reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business.

Get Free Full PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) at: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-mesothelioma-treatment-market

The growth trend forecasted on account of a thorough examination offers in-depth information regarding the Mesothelioma Treatment Market. This global market report offers research and consulting services focused on achieving competitive leverage, with acquiring and preserving market position as key aims of the program.

Prominent Key Players Covered in the report:

Eli Lilly and Company, AstraZeneca, F. Hoffmann-La Roche Ltd, Pfizer Inc., Ono Pharmaceutical Co. Ltd, Bayer AG, Teva Pharmaceuticals Industries Ltd, GlaxoSmithKline plc, Sun Pharmaceuticals Industries Ltd, Bristol-Myers Squibb Company, Novartis AG, Johnson & Johnson Services, Inc., AbbVie Inc., Amgen, Inc., and others.

Key Pointers Covered in the Mesothelioma Treatment Market Industry Trends and Forecast to 2027

A complete value chain of the global Mesothelioma Treatment market is presented in the research report. It is associated with the review of the downstream and upstream components of the Mesothelioma Treatment Market. The market is spliton the basis of the categories of products and clientapplication segments. The market analysis demonstrates the expansion of each segment of the global Mesothelioma Treatment market. The research report assists the user in taking a decisive step on the way tobe a milestone ingrowingandexpandingtheirorganizationsinside theworldwideMesothelioma Treatment market.

Major Regions as Follows:

North America (USA, Canada and Mexico)

Europe (Germany, France, the United Kingdom, Netherlands, Russia , Italy and Rest of Europe)

Asia-Pacific (China, Japan, Australia, New Zealand, South Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia, rest of countries etc.)

Middle East and Africa (Saudi Arabia, United Arab Emirates, Israel, Egypt, Nigeria and South Africa)

How Does This Market Insights Help?

Why choose us:

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=global-mesothelioma-treatment-market

The report highlights current and future market trends and carries out an analysis of the effect of buyers, substitutes, new entrants, competitors, and suppliers on the market. The key topics that have been explained in this Mesothelioma Treatment market report include market definition, market segmentation, key developments, competitive analysis and research methodology.

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Market Drivers

Market Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

In conclusion, the Mesothelioma Treatment Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report Give information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability inspection and venture return investigation.

For More Information or Query or Customization before Buying, Visit at: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-mesothelioma-treatment-market

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

Read more here:

Mesothelioma Treatment Market Sales, Price, Revenue, Gross Margin and Industry Share 2020 2027 - Owned

Unproven ‘stem cell’ therapies for COVID-19 pose harm to public, says UB expert – UB Now: News and views for UB faculty and staff – University at…

Be wary of stem cell therapy as a preventative treatment for COVID-19, warns Laertis Ikonomou, a UB expert on stem cell and gene therapies.

While stem cell therapy, such as bone marrow transplantation, may be used to treat a limited number of diseases and conditions, there are currently no clinically tested or government-approved cell therapies available for the treatment or prevention of COVID-19, says Ikonomou, associate professor of oral biology in the School of Dental Medicine.

He urges the public to exercise caution as the nation experiences a rise in businesses offering direct-to-consumer, unproven and unsafe stem cell therapies that promise to prevent COVID-19 by strengthening the immune system or improving overall health.

What these patients are actually sold is false hope, he says. These businesses are continuously transforming and reinventing themselves, but the common thread is that they offer potentially dangerous treatments based on unproven science.

Ikonomou is also the chair of the International Society for Cell and Gene Therapy (ISCT) Presidential Task Force on the Use of Unproven and/or Unethical Cell and Gene Therapy.

Stem cell therapy involves the conversion of stem cells into specific types of cells, such as heart or blood cells. These cells are then transplanted into a patient to promote healing.

While there are companies that carefully develop cell-based treatments following established regulatory and ethical standards, there has also been an explosion of businesses since the mid-2000s that advertise directly to consumers and evade regulations to provide unsafe and ineffective treatments, he says.

These businesses operate in gray regulatory areas, frequently branding stem cell therapies as medical interventions rather than therapeutic drugs to avoid the need for U.S. Food and Drug Administration (FDA) approval, Ikonomou says, adding that according to published research, there are more than 1,000 of these unsafe businesses in the U.S.

They offer purported stem cell therapies for nearly every condition imaginable, from diabetes and autism to Alzheimers disease. There are also reports of people suffering physical harm including blindness and death from unsafe stem cell interventions, such as drawing and reinjecting patients with their own fat cells, he says.

Im not surprised that a lot of these businesses went into COVID treatments, says Ikonomou. They went where the money is and took advantage of peoples fears.

The treatments range in price from a few thousand to tens of thousands of dollars, and often patients are encouraged to receive the expensive infusions every few months. Many people go into severe debt to acquire these ineffective treatments, he says.

This year, the FDA has issued several letters to offending businesses, including those advertising cell therapies for COVID-19, says Ikonomou. The Federal Trade Commission has also cracked down on misleading advertising from stem cell therapy clinics, he says.

However, many of these clinics are small and difficult to track. Patient prudence is key to avoiding harmful interventions, he says.

Ikonomou shares a list of steps the public can take to ensure a stem cell therapy is safe, proven and ethical.

Ikonomou also urges patients to share any questions they have with their physicians, who often are the gatekeepers for medical treatment. His best advice to patients: If something sounds too good to be true, it probably isnt true.

For information on safe and ethical cell therapies, visit the ISCT website.

See the rest here:

Unproven 'stem cell' therapies for COVID-19 pose harm to public, says UB expert - UB Now: News and views for UB faculty and staff - University at...

Future Prospects of Animal Stem Cell Therapy Market 2020 | Trends, Growth Demand, Opportunities & Forecast To 2026 | Medivet Biologics LLC,…

Animal Stem Cell Therapy Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Animal Stem Cell Therapy Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Get the PDF Sample Copy of This Report:

https://www.a2zmarketresearch.com/sample?reportId=37602

Top Key Players Profiled in This Report:

Medivet Biologics LLC, VETSTEM BIOPHARMA, J-ARM, U.S. Stem Cell, Inc, VetCell Therapeutics, Celavet Inc., Magellan Stem Cells, Kintaro Cells Power, Animal Stem Care, Animal Cell Therapies, Cell Therapy Sciences, Animacel

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Animal Stem Cell Therapy market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Animal Stem Cell Therapy markets trajectory between forecast periods.

Get up to 20% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=37602

Reasons for buying this report:

Table of Contents:

Global Animal Stem Cell Therapy Market Research Report

Chapter 1 Animal Stem Cell Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Animal Stem Cell Therapy Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=37602

Read more:

Future Prospects of Animal Stem Cell Therapy Market 2020 | Trends, Growth Demand, Opportunities & Forecast To 2026 | Medivet Biologics LLC,...

Placental Stem Cell Collection and Storage Market 2020 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2026 – Market…

The prime objective of GlobalPlacental Stem Cell Collection and Storage Market report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 30 major countries. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Impact of Covid-19 in Placental Stem Cell Collection and Storage Market: Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Placental Stem Cell Collection and Storage market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Download FREE Sample Copy of Placental Stem Cell Collection and Storage Report @https://www.crediblemarkets.com/sample-request/placental-stem-cell-collection-and-storage-market-922846

By Market Players:AmericordPluristem TherapeuticsPSTICelularityCryobankReeLabsChina Cord Blood CorporationMesoblast LimitedAmericord RegistryLifebankUSAOcata TherapeuticsStemcyteCryoviva IndiaCaladrius BiosciencesH&B GroupViacordCryo-CellCBR Systems, Inc.Cells4LifeSmart Cells International Ltd.Cordlife

By TypePlacental Subtopotent Stem CellsPlacental Hematopoietic Stem CellsPlacental Mesenchymal Stem Cells (MSC)Placental Maternal Pluripotent Stem Cells

By ApplicationCell TherapyBeauty ProductsOther

Geographically, the detailed analysis of consumption, revenue, and market share and growth rate, historic and forecast of the following regions:

United States, Canada, Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, China, Japan, South Korea, Australia, India, Taiwan, Indonesia, Thailand, Philippines, Malaysia, Brazil, Mexico, Argentina, Columbia, Chile, Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of the World

Enquiry before buying this report @ https://www.crediblemarkets.com/enquire-request/placental-stem-cell-collection-and-storage-market-922846

Some Points from Table of Content

Covid-19 Impact on Global Placental Stem Cell Collection and Storage Industry Research Report 2020 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2026

Chapter 1 Report OverviewChapter 2 Global Placental Stem Cell Collection and Storage Market Trends and Growth StrategyChapter 3 Global Placental Stem Cell Collection and Storage Market Players ProfilesChapter 4 Global Placental Stem Cell Collection and Storage Market Competition by Market PlayersChapter 5 Global Placental Stem Cell Collection and Storage Production by Regions (2015-2020)Chapter 6 Global Placental Stem Cell Collection and Storage Consumption by Region (2015-2020)Chapter 7 Global Placental Stem Cell Collection and Storage Production Forecast by Regions (2021-2026)Chapter 8 Global Placental Stem Cell Collection and Storage Consumption Forecast by Regions (2021-2026)Chapter 9 Global Placental Stem Cell Collection and Storage Sales by Type (2015-2026)Chapter 10 Global Placental Stem Cell Collection and Storage Consumption by Application (2015-2026)Chapter 11 Global Placental Stem Cell Collection and Storage Manufacturing Cost AnalysisChapter 12 Global Placental Stem Cell Collection and Storage Marketing Channel, Distributors, Customers and Supply ChainChapter 13 Analysts Viewpoints/ConclusionsChapter 14 Disclaimer

Grab Maximum Discount on Placental Stem Cell Collection and Storage Market Research Report @https://www.crediblemarkets.com/discount-request/placental-stem-cell-collection-and-storage-market-922846

Points Covered in The Report

About Credible Markets

Credible Markets has emerged as a dependable source for the market research needs of businesses within a quick time span. We have collaborated with leading publishers of market intelligence and the coverage of our reports reserve spans all the key industry verticals and thousands of micro markets. The massive repository allows our clients to pick from recently published reports from a range of publishers that also provide extensive regional and country-wise analysis. Moreover, pre-booked research reports are among our top offerings.

Contact Us

Credible Markets Analytics

99 Wall Street 2124 New York, NY 10005

US Contact No: +1(929)-450-2887

Email: [emailprotected]

Ask for customization @https://www.crediblemarkets.com/custom-research

Originally posted here:

Placental Stem Cell Collection and Storage Market 2020 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2026 - Market...

Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics’ First-In-Class EGFR Dual-targeting CAR for NK Cell Treatment of…

DetailsCategory: DNA RNA and CellsPublished on Monday, 03 August 2020 17:50Hits: 540

Michael A. Caligiuri, MD joins Cytovia Scientific Advisory Board

NEW YORK, NY and MONROVIA, CA, USA I August 03, 2020 I Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing natural killer (NK) immunotherapies for cancer, today announces that it has acquired worldwide rights from CytoImmune Therapeutics for its novel EGFR Dual-targeting CAR to be used for NK cell therapy. Cytovia will conduct and finance all future development and will apply the EGFR Dual-targeting CAR to its iPSC CAR NK technology. CytoImmune will receive an upfront equity grant in Cytovia, future development milestones, and royalties.

Dr. Daniel Teper, Chairman and CEO of Cytovia added: We are honored to collaborate with Dr. Caligiuri, a pioneer in translating biological research on NK cells into impactful therapeutics. He has published solid data with intracranial injection of EGFR CAR NK cells to support their clinical development in glioblastoma. Additionally, EGFR is a clinically validated target which will allow us to expand the use of NK cellular therapy in multiple solid tumors.

Pre-clinical proof of concept data with intracranial administration of the EGFR Dual-targeting CAR-NK cells for the treatment of glioblastoma has been published in Nature Scientific Reports. The EGFR Dual-targeting CAR targets glioblastoma cells expressing EGFR wild-type and/or the mutant EGFR vIII. A single intracranial injection of EGFR CAR NK cells reduced the growth of glioblastoma and showed a statistically significant improvement in survival in animal models. The intracranial injection of the EGFR CAR NK cells remained localized in the brain without entering the systemic circulation or infiltrating extracranial organs or tissues, thus limiting toxicity.

Michael A. Caligiuri, MD, the scientific founder of CytoImmune, is joining the Cytovia Scientific Advisory Board. Dr Caligiuri is the Deana and Steve Campbell Physician in Chief Distinguished Chair and President of the City of Hope Cancer Center in Duarte, CA. Dr. Caligiuri is a world-renowned physician, scientist, builder, innovator, leader and visionary. He was elected a Member of the National Academy of Medicine for his work on NK cell biology and its clinical applications. He is a past President of the American Association for Cancer Research (AACR).

Dr Caligiuri commented: CAR NK cell therapy has the potential to transform cancer outcomes. We are excited to partner with Cytovia to rapidly bring EGFR Dual-targeting CAR NK cells, a next generation therapy, to patients with the ultimate goal of curing glioblastoma. Cytovias off-the-shelf iPSC CAR NK cell technology should increase the access to precision immunotherapy for many cancer patients.

ABOUT CAR NK CELL THERAPYChimeric Antigen Receptors (CAR) are fusion proteins that combine an extracellular antigen recognition domain with an intracellular co-stimulatory signaling domain. Natural Killer (NK) cells are modified genetically to allow insertion of a CAR. CAR NK cell therapy has demonstrated initial clinical relevance without the limitations of CAR-T, such as Cytokine Release Syndrome, neurotoxicity or Graft vs Host Disease (GVHD). Induced Pluripotent Stem Cells (iPSC) - derived CAR NKs are naturally allogeneic, available off-the-shelf and may be able to be administered on an outpatient basis. Recent developments with iPSC, an innovative technology, allow large quantities of homogeneous genetically modified CAR NK cells to be produced from a master cell bank, and thus hold promise to expand access of cell therapy for many patients.

ABOUT GLIOBLASTOMAGlioblastoma affects 290,000 new patients every year worldwide. Chemotherapy and radiotherapy lack specificity and provide limited efficacy along with high toxicity. The median overall survival from the time of diagnosis is only 14.6 months. Systemic and particularly intracranial or intratumoral immunotherapy, which can target localized and infiltrating cells, has shown initial promise in early clinical trials.

ABOUT CYTOVIA THERAPEUTICS, INCCytovia Therapeutics Inc is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer and severe acute infectious diseases. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF) and the Hebrew University of Jerusalem. Learn more atwww.cytoviatx.com

ABOUT CYTOIMMUNE THERAPEUTICSCytoImmune Therapeutics (CytoImmune) is biotechnology company focused on the application of proprietary chimeric antigen receptors (CAR) for use in both off-the-shelf human natural killer (NK) cells and autologous cytotoxic effector T cells in the treatment of liquid and solid tumors. Our CoalesceNT platform harnesses the power of both a specific CAR and a different secretory bispecific antibody in a single construct to coordinate an immune response with CAR NK cells, cytolytic effector T cells, NK-T cells and g/d T cells. This combination of NK- and T-cell therapy expedites time-to-treatment and delivers a dynamic response that reflects both innate and adaptive immunity in an effort to reduce tumor evasion and the incidence of cancer recurrence.

Learn more at http://www.cytoimmune.com

SOURCE: Cytovia Therapeutics

Visit link:

Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics' First-In-Class EGFR Dual-targeting CAR for NK Cell Treatment of...

MediVet Biologics Rebrands as Ardent Animal Health – PR Web

Ardent Animal Health

LEXINGTON, Ky. (PRWEB) August 03, 2020

Introducing Ardent Animal Health MediVet Biologics rebrands company and positions its platform of innovative products for transformative growth

MediVet Biologics is announcing a new name and a new look for its corporate brand as it relaunches itself as Ardent Animal Health.

In the years since its inception in 2016, the new Ardent Animal Health has developed into a global leader in the areas of veterinary regenerative medicine and oncology solutions for animals. The companys core mission is to develop affordable, innovative treatments for animal cancer and disease while supporting its veterinary partners in their efforts to make a positive impact on pet health.

The name Ardent captures the spirit of our organization as a company with fiery passion for innovation guided by compassion for the well-being of animals. The new brand translates the enormous and unique impact our veterinarian customers make each day in the lives of their patients. Our aim is to leverage our brand to accelerate connecting pet owners seeking advanced care to our expanding network of progressive veterinarian partners around the world," says Thomas Masterson, President of Ardent Animal Health.

Under its former brand of MediVet Biologics, Ardent Animal Health developed the first in-clinic adipose regenerative stem cell therapy kit, ActiStem Therapy. A major scientific advancement in animal regenerative medicine, the product offers an economic solution for owners of pets suffering from osteoarthritis, hip dysplasia, and ligament and cartilage injuries, as well as numerous mobility ailments. In addition to regenerative cells from fat, Ardent-certified hospitals offer other biologic treatments such as Platelet Rich Plasma, or PRP, a blood-derived treatment gaining popularity in human sports medicine.

Ardent Animal Health is unique for a company of its size, as it has surrounded its current and pipeline products with strong intellectual property and multiple collaborative university studies. This has allowed the company to grow, cementing its current technology, and look toward the future for its stem cell-based product pipeline candidates. Ardent Animal Health will launch with an extensive following of pet owners and veterinarians positively impacted by its products and services. The studies, passionate customers, and patient outcomes continue to provide momentum for the companys technology and products. Over 20,000 veterinary patients have received treatment of an Ardent Animal Health regenerative product or service.

Ardent Animal Health has also introduced cutting edge science to fight against canine cancer with its cancer vaccine service, K9- ACV, an immunotherapy vaccine generated from a canine patients own cancerous tumor. K9-ACV is designed to stimulate the canine patient's immune response to attack the cancer. We are looking to meet an unmet need in pet cancer, at the family veterinarian office when needed. 50% of dogs over the age of ten will develop some type of cancer, so there is a need for a broadly applicable approach that can improve lifespan at a reasonable cost. Our preliminary studies and extensive market research indicate this approach will provide access to pets that need it, Masterson said.

According to Mr. Masterson, the companys strength in these core innovative therapeutic areas will allow the organization to accelerate growth following its recent transition in both leadership and ownership. As a portfolio company of STUCK Fund 1, based in Milwaukee, WI, Ardent Animal Health will continue to develop novel approaches for early disease detection and treatments, with a focus on precision medicine for pets in need.

We will continue to focus much of our strategy in creating novel products and services utilized in veterinary hospitals. We believe that this approach is key to the future of animal health. It is important not only for value creation but to ensure veterinarians have the ability to diagnose and treat their patients with the same leading-edge strategies underway in human health. Our animal family members deserve it.

DisclaimerExperimental Cancer Vaccines created by Ardent Animal Health are provided under 9 CFR 103.3 via USDA Center for Veterinary Biologics oversight for use under supervision/prescription of a licensed veterinarian. Safety & efficacy have not been yet established.

About Ardent Animal Health

Since 2016 Ardent Animal Health based near Lexington, KY, has provided advanced medical strategies to veterinary hospitals around the world. Ardent provides regenerative medicine treatments such as ActiStem Therapy and PureVet PRP to veterinarians for pain and disease in companion and equine patients. Additionally, Ardent Animal Health is pursuing advanced strategies for detection and treatment of canine cancer. Through creation of its own intellectual property and strategic licensing partners, the companys portfolio includes current and future offerings aimed to raise the standard for animal healthcare.

Home

About STUCK Fund 1

Ardent Animal Health represents an innovation-focused element of the STUCK Fund 1 portfolio, as Ardent competes in the fast-growing and recession-resistant pet health sector. STUCK Fund 1, based in Milwaukee, WI, was founded in 2014 to live out the lessons the investment firms founders learned from growing its business into an international, $100 million organization. STUCK founders were honored with numerous accolades in their prior ventures, including the Muskego Manufacturing Business of the Year award and the Waukesha Business Alliance Manufacturing Business of the Year honor, among several others. Currently, the investment firm supports like-minded entrepreneurs to accelerate and sustain the growth of their businesses.

https://getunstuck.com/about/

Media Contact: Matt Yeich (859)885-7111 matt@ardentanimalhealth.com

Share article on social media or email:

See the original post here:

MediVet Biologics Rebrands as Ardent Animal Health - PR Web

UPDATE – Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics’ First-In-Class EGFR Dual-targeting CAR for NK Cell Treatment of…

NEW YORK and MONROVIA, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing natural killer (NK) immunotherapies for cancer, today announces that it has acquired worldwide rights from CytoImmune Therapeutics for its novel EGFR Dual-targeting CAR to be used for NK cell therapy. Cytovia will conduct and finance all future development and will apply the EGFR Dual-targeting CAR to its iPSC CAR NK technology. CytoImmune will receive an upfront equity grant in Cytovia, future development milestones, and royalties.

Dr. Daniel Teper, Chairman and CEO of Cytovia added: We are honored to collaborate with Dr. Caligiuri, a pioneer in translating biological research on NK cells into impactful therapeutics. He has published solid data with intracranial injection of EGFR CAR NK cells to support their clinical development in glioblastoma. Additionally, EGFR is a clinically validated target which will allow us to expand the use of NK cellular therapy in multiple solid tumors.

Pre-clinical proof of concept data with intracranial administration of the EGFR Dual-targeting CAR-NK cells for the treatment of glioblastoma has been published in Nature Scientific Reports. The EGFR Dual-targeting CAR targets glioblastoma cells expressing EGFR wild-type and/or the mutant EGFR vIII. A single intracranial injection of EGFR CAR NK cells reduced the growth of glioblastoma and showed a statistically significant improvement in survival in animal models. The intracranial injection of the EGFR CAR NK cells remained localized in the brain without entering the systemic circulation or infiltrating extracranial organs or tissues, thus limiting toxicity.

Michael A. Caligiuri, MD, the scientific founder of CytoImmune, has been invited and is planning to join the Cytovia Scientific Advisory Board. Dr Caligiuri is the Deana and Steve Campbell Physician in Chief Distinguished Chair and President of the City of Hope National Medical Center in Duarte, CA. Dr. Caligiuri is a world-renowned physician, scientist, builder, innovator, leader and visionary. He was elected a Member of the National Academy of Medicine for his work on NK cell biology and its clinical applications. He is a past President of the American Association for Cancer Research (AACR).

Dr Caligiuri commented: CAR NK cell therapy has the potential to transform cancer outcomes. We are excited to partner with Cytovia to rapidly bring EGFR Dual-targeting CAR NK cells, a next generation therapy, to patients with the ultimate goal of curing glioblastoma. Cytovias off-the-shelf iPSC CAR NK cell technology should increase the access to precision immunotherapy for many cancer patients.

ABOUT CAR NK CELL THERAPYChimeric Antigen Receptors (CAR) are fusion proteins that combine an extracellular antigen recognition domain with an intracellular co-stimulatory signaling domain. Natural Killer (NK) cells are modified genetically to allow insertion of a CAR. CAR NK cell therapy has demonstrated initial clinical relevance without the limitations of CAR-T, such as Cytokine Release Syndrome, neurotoxicity or Graft vs Host Disease (GVHD). Induced Pluripotent Stem Cells (iPSC) - derived CAR NKs are naturally allogeneic, available off-the-shelf and may be able to be administered on an outpatient basis. Recent developments with iPSC, an innovative technology, allow large quantities of homogeneous genetically modified CAR NK cells to be produced from a master cell bank, and thus hold promise to expand access of cell therapy for many patients.

ABOUT GLIOBLASTOMAGlioblastoma affects 290,000 new patients every year worldwide. Chemotherapy and radiotherapy lack specificity and provide limited efficacy along with high toxicity. The median overall survival from the time of diagnosis is only 14.6 months. Systemic and particularly intracranial or intratumoral immunotherapy, which can target localized and infiltrating cells, has shown initial promise in early clinical trials.

ABOUT CYTOVIA THERAPEUTICS, INCCytovia Therapeutics Inc is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer and severe acute infectious diseases. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF) and the Hebrew University of Jerusalem. Learn more atwww.cytoviatx.com

ABOUT CYTOIMMUNE THERAPEUTICSCytoImmune Therapeutics (CytoImmune) is biotechnology company focused on the application of proprietary chimeric antigen receptors (CAR) for use in both off-the-shelf human natural killer (NK) cells and autologous cytotoxic effector T cells in the treatment of liquid and solid tumors. Our CoalesceNT platform harnesses the power of both a specific CAR and a different secretory bispecific antibody in a single construct to coordinate an immune response with CAR NK cells, cytolytic effector T cells, NK-T cells and g/d T cells. This combination of NK- and T-cell therapy expedites time-to-treatment and delivers a dynamic response that reflects both innate and adaptive immunity in an effort to reduce tumor evasion and the incidence of cancer recurrence.

Learn more at http://www.cytoimmune.com

Contact for media enquiries Sophie BadrVice President, Corporate AffairsSophie.badre@cytoviatx.com1(929) 317 1565

Will RosselliniPresidentwill@cytoimmune.com 1(469) 222 2350

Read more from the original source:

UPDATE - Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics' First-In-Class EGFR Dual-targeting CAR for NK Cell Treatment of...

FDA-approved treatment puts rare cancer with skin manifestations on the map – Dermatology Times

A small group of scientists and clinicians are trying to build awareness of this cancer, and how to diagnose and treat it. While this rare and aggressive hematologic malignancy hasnt had a standardized therapeutic approach in the past, that is also changing. The FDA approved tagraxofusp (Elzonris, Stemline) in 2019 as the first medication indicated to treat BPDCN, according to a drug review published June 24, 2020 in the journal Expert Review of Anticancer Therapy.1

Progress aside, theres still a long way to go in creating awareness among dermatologists, primary care physicians, emergency department providers and pediatricians all of whom are most likely to encounter people with possible BPDCN, says Naveen Pemmaraju,M.D., associate professor in the department of leukemia at The University of Texas MD Anderson Cancer Center. Dr. Pemmaraju is senior author on the recent Expert Review of Anticancer Therapy paper, and he led the pivotal study published in April 2019 in the New England Journal of Medicine that led to the FDAs approval of tagraxofusp for the treatment of BPDCN.2

Having the clinical trial is great, but now that the drug is commercially available there was a call for what are the practical considerations for Tagraxofusp in BPDCN? Dr. Pemmaraju says. Thats why we wrote this paper.

Dermatologists, take noteDr. Pemmaraju points to three stand-out practical considerations for providers.

One is that most people in medicine have yet to even hear about the disease, he says. When people on the frontlines see skin lesions, the only way theyre going to know whether its BPDCN is with a biopsy. Tissue is the issue, as they say. If something looks irregular, abnormal and if its clinically indicated to do a biopsy, do a biopsy. A lot of these patients get mistaken for other diseases, infections, other cancers. So, I think the biopsy is important.

The need for expert review goes along with the first practical consideration.

CD123 (interleukin-3 receptor alpha unit) is overexpressed in 100% of BPDCN patients. But thats not the only way to differentiate this cancer on biopsy. CD123, CD4, CD56 as the golden triad of BPDCN, according to Dr. Pemmaraju.

Now we know there are other markers, TCL1, TCF 4, CD303 and others. When you put together these three to six markers, it helps you distinguish BPDCN, which is extraordinarily rare compared to the more common cancers like acute myeloid leukemia (AML), cutis, cutaneous t-cell lymphoma. Obviously, this differentiates completely from skin infections and all these other noncancer entities, Dr. Pemmaraju says.

The second practical consideration is that, although rare diseases commonly have limited-to-no treatment options, a therapy for BPDCN exists and more are being investigated. Studies suggest that BPDCN incidence is as low as 0.44% of all hematologic cancers and 0.7% of cutaneous lymphomas, according to the paper. Despite the low numbers, BPDCN treatment is available with tagraxofusp. Researchers are also conducting multiple clinical trials for BPDCN drugs in development, including the B-cell lymphoma-2 (BCL-2) inhibitor, venetoclax, and a chimeric antigen receptor (CAR) T-cell therapy.

The third consideration: The significance of dermatologists and dermatopathologists roles in BPDCN diagnosis.

As we educate our fellow hematologists/oncologists, we must continue to educate dermatologists, many of whom are going to see this disease for the very first time in the clinic before anybody else. I believe BPDCN will soon appear on dermatology and derm-path board exams, Dr. Pemmaraju says.

BPDCN skin lesions usually present as dark and purplish and can be maculopapular.

I would say clinically there is a somewhat distinct look, although I would add the caveat that these lesions act heterogeneously, he says.

Focusing on TagraxofuspResearchers reported that tagraxofusp, aCD123-directed cytotox, demonstrated efficacy in BPDCN patients along with an overall manageable safety profile, according to the NEJM study.

A historically deadly disease, BPDCNs median overall survival after chemotherapy had been 8 to 14 months, according to Dr. Pemmaraju. Hematopoietic stem cell transplant might prolong survival in patients healthy enough to have the stem cell transplant.

Among the 29 previously untreated patients, the survival rates of 59% at 18 months and 52% at 24 months rates that were influenced by the number of patients who went into remission after tagraxofusp therapy and could thus undergo hematopoietic stem-cell transplantation represent an improvement over rates in historically published data. We also observed a 67% overall response rate among previously treated patients. Notably, we report a meaningful survival with tagraxofusp among patients with relapsed or refractory disease (median overall survival, 8.5 months), Dr. Pemmaraju and colleagues report in the NEJM.

Interestingly, patients skin lesions went away rapidly in the vast majority of people treated with tagraxofusp, according to Dr. Pemmaraju.

Capillary leak syndrome emerged as the most drug-associated serious adverse, manifested by edema, tachycardia, hypoalbuminemia and hypotension.

There also is the issue of drug resistance. Researchers have found, in vivo, that resistance to tagraxofusp in cell lines is associated with decreased DPH1 expression and azacitadine might reverse tagraxofusp resistance.

More research is needed to study how combining tagraxofusp with other targeted therapies may improve outcomes. Research also is needed to study tagraxofusp use in pediatric patients. The FDAs approval is for tagraxofusp is as first-line therapy for BPDCN for adults and children ages 2 years and older. But only a small number of pediatric patients have been treated so far, the authors report.

DisclosureMD Anderson funded the study. Dr. Pemmaraju has received research funding/clinical trials support from Affymetrix, SagerStrong Foundation, Novaris, Stemline, Samus, AbbVie, Cellectis, Daiichi Sankyo, and Plexxikon.

References

1. Lee SS, Mccue D, Pemmaraju N. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm. Expert Rev Anticancer Ther. 2020;:1-8.

2. Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019;380(17):1628-1637.

Go here to read the rest:

FDA-approved treatment puts rare cancer with skin manifestations on the map - Dermatology Times

‘Year of Preparations for the Next Fifty Years’ will contribute to country’s development process – WAM EN

ABU DHABI, 3rd August, 2020 (WAM) -- In 2020, the UAEs achievements, most notably the launch of the Hope Probe to Mars and the operation of Unit 1 of the Barakah Nuclear Power Plant, have proven that the "Year of Preparations for the Next Fifty Years" will significantly contribute to the countrys development process.

Despite the difficult circumstances facing the world caused by the coronavirus, COVID-19, pandemic, the UAE has succeeded in turning challenges into opportunities for innovation and development, which is reflected in its approach to limiting the spread of the virus through a range of creative measures, such as developing technology to discover the virus using lasers that generate results in a record time, using stem cell therapy for patients, and participating in global efforts to find a vaccine.

In 2020, the UAEs achievements reflect the national ambitions and wisdom of its leadership. The Hope Probe project involved nearly 200 Emirati engineers and researchers, who worked hard for six years to fulfil the UAE's dream to reach the Red Planet.

The Barakah Nuclear Power Plant also highlights the UAEs efforts to build the capacities of national cadres in this sector. Nearly 244 employees work for the Federal Authority for Nuclear Regulation, FANR, with 67 percent being Emiratis, of which 45 percent are in leading and managerial positions. Women also account for over 40 percent of the Authoritys employees.

Once all four units of the plant are commercially operating, the UAE's Barakah Nuclear Energy Plant will produce up to 25 percent of the country's electricity requirements while in parallel preventing the release of 21 million tons of carbon emissions each year.

On the level of combating COVID-19, Emirati national cadres and institutions joined the front line since the first day to discover the first case in the country, and contributed to achieving milestones at the global level.

In May, a patent was granted by the Ministry of Economy for the development of an innovative and promising treatment for COVID-19 infections using stem cells. The treatment was developed by a team of doctors and researchers at the Abu Dhabi Stem Cell Center, ADSCC, and involves extracting stem cells from the patients own blood and reintroducing them after activating them.

QuantLase Imaging Lab, the medical-research arm of the Abu Dhabi Stock Exchange-listed International Holdings Company, IHC, announced that it has developed novel equipment which enables for much faster mass screenings, with test results available in seconds and allowing testing on a wider scale.

The technology will reinforce the UAEs position as a hub of research and innovation, as scientists around the world scramble to devise a faster method of testing for patients suspected to have been infected with the coronavirus and potentially identifying carriers before they become infectious.

The first World Health Organisation, WHO, enlisted global clinical Phase III trial of Sinopharm CNBGs inactivated vaccine to combat COVID-19 started in Abu Dhabi.

The worlds first Phase III trial is the result of a cooperation partnership between Abu Dhabi based G42 Healthcare, currently at the forefront of the battle against COVID-19 in the UAE, and Sinopharm CNBG, the worlds sixth-largest vaccine manufacturer, ranked 169th on the Fortune Global 500 list of 2018.

The trials are being operated by health practitioners from Abu Dhabi Health Services, SEHA, who are providing facilities at five of their clinics in Abu Dhabi and Al Ain in addition to a mobile clinic to ensure the trials are readily accessible to volunteers participating in the programme.

The rest is here:

'Year of Preparations for the Next Fifty Years' will contribute to country's development process - WAM EN

Tesla shares sag as analyst flags mind-boggling valuation – The Detroit News

Esha Dey, Bloomberg Published 11:56 a.m. ET July 28, 2020 | Updated 12:00 p.m. ET July 28, 2020

Tesla Inc. has grown bigger than Toyota and Volkswagen combined thanks to a rally more befitting a technology stock than a car maker, and buying it now is probably a mistake for anyone but day traders, an analyst said Tuesday in downgrading the stock.

Risks to the valuation include the possibility a new Tesla model will cannibalize sales of an older one, and rising competition in the electric vehicle market in general, wrote Sanford C. Bernstein analyst Toni Sacconaghi. While Elon Musks company has recently executed well on its strategy, the stocks 481% gain in the past year likely reflects more good news than is probably forthcoming, he said in a note to clients.

In this Monday, May 11, 2020 file photo, a man wearing a mask walks through the Tesla plant parking lot in Fremont, Calif.(Photo: Ben Margot, AP, File)

Let us be clear: this is a valuation call, Sacconaghi wrote, calling the market value mind-boggling. He lowered his rating to the equivalent of a sell from hold, and maintained his price target of $900, representing a 42% discount to Mondays close. The shares fell as much as 4% to $1,477.60 on Tuesday.

Sacconaghis downgrade follows an advance that pushed the companys valuation over $300 billion at one point, amid investor optimism about strong second-quarter results, a possible inclusion into the S&P 500 Index, and anticipation for new battery technology.

The analyst noted, however, that trying to predict Teslas stock direction in the near term could be a fools game.

Expectations appear achievable/beatable, the forthcoming Battery Day could be noteworthy, and there is strong price momentum in both Tesla and among growth stocks more broadly, the analyst said.

Sacconaghi said he would change his mind if Tesla ultimately demonstrates unique progress in autonomous driving or other software, leading to high margins over time.

The current valuation has led some investors to start valuing Tesla as if it were a technology stock. Sacconaghi noted its market value is now bigger than Toyota and Volkswagen combined, which collectively make 20 million cars every year, compared to Teslas expected 500,000 cars this year.

Separately, Tesla said in a regulatory filing early Tuesday that it has cleared out its balance of deferred revenue related to sales of regulatory credits to other automakers. Without the sale of credits to automakers that are out of compliance with emissions rules, Tesla wouldnt have earned a profit last quarter.

Chief Financial Officer Zachary Kirkhorn said last week that while Tesla expects regulatory credit revenue to roughly double this year, it assumes those sales wont make a significant contribution to the business in the future. Deferred revenue went to zero as of June 30, from $140 million at the end of the first quarter.

Read or Share this story: https://www.detroitnews.com/story/business/autos/2020/07/28/tesla-shares-sag-analyst-flags-mind-boggling-valuation/112529796/

Here is the original post:

Tesla shares sag as analyst flags mind-boggling valuation - The Detroit News

Quantum Computing Explained for Investors – Barron’s

Quantum computing was named a breakout technology in 2017 by the Massachusetts Institute of Technology. It showed up again on the list for 2020. Does that mean quantum computing is ready for prime time? Possibly. That is good news for the world, but the problem is few know what a quantum computer actually doesand investors dont know what quantum computing means for their portfolio.

Where to start? Microsoft (ticker: MSFT) is a large quantum player. And looking at its quantum business can help frame the issue for investorsand anyone else.

Its helpful to start a few steps back from Microsofts quantum aspirations.

Many people have heard of the quantum realm, thanks in large part to Walt Disneys (DIS) Marvel Cinematic Universe. The Avengers, after all, defeated Thanos in Avengers: Endgamethe highest-grossing film of all timewith the help of quantum tunnels. And the Guardians of the Galaxy navigated a quantum asteroid field in their latest stand-alone film.

In the quantum asteroid field, rocks popped in and out of existence. The idea being that in the quantum realm, almost anything is possible. Quantum has become an analogy for weird, counterintuitive outcomes.

Quantum physics does indeed dictate a bunch of weird things, including particlesnot the size of asteroidspopping in and out of existence.

Physicist Richard Feynman said once that all people need to know about quantum physics is the double-slit experiment.

In the experiment, a single electronwhich is a negatively-charged subatomic particlepasses through both slits at the same time. Very weird. But that is because particles have wavelike properties. A wave of water would hit both slits.

So an electron behaves like a wave. OK. But heres the thing, if someone watches the experiment unfoldputting a detector in front of the slitsthe electron stops acting like water. It goes back to being a particle. Weird.

That, curiously, has some benefits for a computer. In a traditional computer, a bitthe basic unit of computing powercan have a value of one or zero. A quantum bit, more commonly called a qubit, is the basic unit of quantum computing. It can have a value of one or zero or anything in betweenat the same time.

There are other things qubits can do, but multiple, simultaneous values makes quantum computers faster. A 64-bit computer can have roughly 18 quintillion (18 with 18 zeros) values. If a computer can do 2 billion values per second, it will take roughly 300 years to go through all potential values.

A 64-bit quantum computer can have, in theory, all 18 quintillion values at once. Go figure.

MIT put quantum computing back on its technology list in 2020 because a quantum computer with 53 qubits built by Google parent Alphabet (GOOGL) did a calculation, in about three minutes, that would have taken a traditional computer 10,000 years.

Quantum supremacy was demonstrated. Great. So when will consumers be buying a quantum desktop, and when will investors be bidding up Alphabet stock on exploding quantum sales?

Not yet.

Qubits are not reliable yet. There is noise, Stephen Jordan, Microsoft quantum principal researcher, told Barrons. People are still working out the hardware. There are, for instance, superconducting qubits, trapped-ion qubits, and topological qubits.

Picking between qubits isnt like beta or VHS, or a Mac versus a PC. With todays computers underlying hardware is the same and 100% reliable, adds Jordan.

The industry is still working out the hardware. To reduce the noise, usually, you take qubits and string a bunch together to make a computing qubit, explains Helmut Katzgraber, Microsoft quantum principal research manager.

Microsoft, of course, is known for software. Maybe that means what the quantum computing industry needs is quantum Intel (INTC), pumping out the quantum equivalent of silicon chips with 1 billion transistors on them. (A transistor can store a bita one or zeroas information.)

For Katzgraber, the qubit hardware industry will be like FPGA, short for field programmable gate arrays, which are integrated circuits that can be configured into ASIC, short for application-specific integrated circuits.

Xilinx (XLNX) makes FPGAs. They get their supply from businesses like Taiwan Semiconductor Manufacturing (TSM), and Taiwan Semi gets silicon from a company like Lam Research (LCRX).

There is now a quantum value chain like that. Honeywell International (HON) can make trapped-ion qubits. That is probably as close as investors have to a quantum supplier at this point.

Hardware doesnt have to come before software and applications though.

We have gone through computer creation before, says Katzgraber. We are doing the whole stackthe software to the qubitsall at once.

That speeds development, but doesnt mean there will be a quantum smartphone soonor sooner than it took to go from mainframe to desktop, to laptop to iPhone. Quantum computing will probably look a little different. These [systems] will live in data centers in the cloud, adds Jordan.

Along with hardware comes apps. And a killer quantum app will help elevate the technology from MITs tech review to the nightly news. There are areas where the existing tech is having an impact. Julie Love, Microsoft quantum applications team leader, tells Barrons about several problems being addressed now from traffic light optimization to industrial catalyst for chemical production.

For now, big tech is big quantum. Google, Microsoft, IBM (IBM), and Amazon.com (AMZN) have quantum aspirations. Honeywell has its toes in quantum waters too. Its tough to buy any of those stock as a quantum investment yet.

Superconductor makers dont talk about quantum computing much in filings either. And superconducting is only a $2 billion industry at the moment.

Quantum computing remains a watch item for investorsalbeit an interesting one.

Write to Al Root at allen.root@dowjones.com

Follow this link:

Quantum Computing Explained for Investors - Barron's

Giant atoms enable quantum processing and communication in one – MIT News

MIT researchers have introduced a quantum computing architecture thatcan perform low-error quantum computations while also rapidly sharing quantum information between processors. The work represents a key advance toward a complete quantum computing platform.

Previous to this discovery, small-scale quantum processors have successfully performed tasks at a rate exponentially faster than that of classical computers. However, it has been difficult to controllably communicate quantum information between distant parts of a processor. In classical computers, wired interconnects are used to route information back and forth throughout a processor during the course of a computation. In a quantum computer, however, the information itself is quantum mechanical and fragile, requiring fundamentally new strategies to simultaneously process and communicate quantum information on a chip.

One of the main challenges in scaling quantum computers is to enable quantum bits to interact with each other when they are not co-located, says William Oliver, an associate professor of electrical engineering and computer science, MIT Lincoln Laboratory fellow, and associate director of the Research Laboratory for Electronics. For example, nearest-neighbor qubits can easily interact, but how do I make quantum interconnects that connect qubits at distant locations?

The answer lies in going beyond conventional light-matter interactions.

While natural atoms are small and point-like with respect to the wavelength of light they interact with, in a paper published today in the journal Nature, the researchers show that this need not be the case for superconducting artificial atoms. Instead, they have constructed giant atoms from superconducting quantum bits, or qubits, connected in a tunable configuration to a microwave transmission line, or waveguide.

This allows the researchers to adjust the strength of the qubit-waveguide interactions so the fragile qubits can be protected from decoherence, or a kind of natural decay that would otherwise be hastened by the waveguide, while they perform high-fidelity operations. Once those computations are carried out, the strength of the qubit-waveguide couplings is readjusted, and the qubits are able to release quantum data into the waveguide in the form of photons, or light particles.

Coupling a qubit to a waveguide is usually quite bad for qubit operations, since doing so can significantly reduce the lifetime of the qubit, says Bharath Kannan, MIT graduate fellow and first author of the paper. However, the waveguide is necessary in order to release and route quantum information throughout the processor. Here, weve shown that its possible to preserve the coherence of the qubit even though its strongly coupled to a waveguide. We then have the ability to determine when we want to release the information stored in the qubit. We have shown how giant atoms can be used to turn the interaction with the waveguide on and off.

The system realized by the researchers represents a new regime of light-matter interactions, the researchers say. Unlike models that treat atoms as point-like objects smaller than the wavelength of the light they interact with, the superconducting qubits, or artificial atoms, are essentially large electrical circuits. When coupled with the waveguide, they create a structure as large as the wavelength of the microwave light with which they interact.

The giant atom emits its information as microwave photons at multiple locations along the waveguide, such that the photons interfere with each other. This process can be tuned to complete destructive interference, meaning the information in the qubit is protected. Furthermore, even when no photons are actually released from the giant atom, multiple qubits along the waveguide are still able to interact with each other to perform operations. Throughout, the qubits remain strongly coupled to the waveguide, but because of this type of quantum interference, they can remain unaffected by it and be protected from decoherence, while single- and two-qubit operations are performed with high fidelity.

We use the quantum interference effects enabled by the giant atoms to prevent the qubits from emitting their quantum information to the waveguide until we need it. says Oliver.

This allows us to experimentally probe a novel regime of physics that is difficult to access with natural atoms, says Kannan. The effects of the giant atom are extremely clean and easy to observe and understand.

The work appears to have much potential for further research, Kannan adds.

I think one of the surprises is actually the relative ease by which superconducting qubits are able to enter this giant atom regime. he says. The tricks we employed are relatively simple and, as such, one can imagine using this for further applications without a great deal of additional overhead.

Andreas Wallraff, professor of solid-state physics at ETH Zurich, says the research "investigates a piece of quantum physics that is hard or even impossible to fathom for microscopic objects such as electrons or atoms, but that can be studied with macroscopic engineered superconducting quantum circuits. With these circuits, using a clever trick, they are able both to protect their giant atom from decay and simultaneously to allow for coupling two of them coherently. This is very nice work exploring waveguide quantum electrodynamics."

The coherence time of the qubits incorporated into the giant atoms, meaning the time they remained in a quantum state, was approximately 30 microseconds, nearly the same for qubits not coupled to a waveguide, which have a range of between 10 and 100 microseconds, according to the researchers.

Additionally, the research demonstrates two-qubit entangling operations with 94 percent fidelity. This represents the first time researchers have quoted a two-qubit fidelity for qubits that were strongly coupled to a waveguide, because the fidelity of such operations using conventional small atoms is often low in such an architecture. With more calibration, operation tune-up procedures and optimized hardware design, Kannan says, the fidelity can be further improved.

See the rest here:

Giant atoms enable quantum processing and communication in one - MIT News

The future of encryption: Getting ready for the quantum computer attack – TechRepublic

PQShield, a spin-out from the UK's Oxford University, is developing advanced cryptographic solutions for hardware, software and communications to protect businesses' data from the quantum threat.

The development of quantum computers poses a cybersecurity problem such as the IT industry has never seen before. All stored data currently deemed secure by modern standards whether that's health records, financial data, customer databases and even critical government infrastructure could, in theory, be cracked by quantum computers, which are capable of effectively short circuiting the encryption we've used to protect that data until now.

Efforts to protect our data from the quantum threat are underway, though whether the issue is being looked at with the urgency it deserves is up for debate. PQShield, a post-quantum cryptography startup spun out of Oxford University, perceives a disconnect between the scale of the threat and the current cyber-readiness of most businesses in 2020, which it is now trying to address.

SEE: Quantum computing: Myths v. Realities (TechRepublic)

"The scale of the quantum attack is just too big to imagine," Dr. Ali Kaafarani, research fellow at Oxford's Mathematical Institute and founder of PQShield, tells TechRepublic.

"The most important part of what we're doing is to educate the market."

Kaafarani is a former engineer at Hewlett-Packard Labs and leads a team of 10 full-time quantum cryptographers, from what he estimates to be a worldwide pool of just a hundred or so. The company is busy working on the development of quantum-secure cryptography encryption solutions for hardware, software and communications that will secure information from future risk, yet can be implemented using today's technology.

This comprises a system on chip (SoC) and software development kit that allow companies to create secure messaging applications, protected by a "post-quantum" variant of the Signal cryptographic protocol. Central to PQShield's technology is that it is designed to work with both legacy systems as well as those expected in the years to come, meaning it could offer protection for everything from keyless cars and other connected devices, to data moving to and from cloud servers.

This, Kaafarani explains, is important owing to the fact that post-quantum cryptography cannot be retrospectively implemented meanwhile data encrypted by modern standards remains open to post-quantum threats. "What we're using right now as end-to-end encryption...is secure now, but people can intercept them and steal encrypted data," he says.

"Once they have access to a quantum computer, they can decrypt them, so confidentiality is threatened in retrospect, because whatever is considered confidential now can be decrypted later on."

Kaafarani also perceives an issue with the current attitudes to remediating cyberattacks, which he likens to applying a band-aid to a repeating problem.

SEE: SSL Certificate Best Practices Policy (TechRepublic Premium)

"That's why we started PQShield to fill in this gap, to lead the way to a smooth and secure transition to the quantum era. There is a real opportunity here to get things right from the beginning."

The startup recently completed a 5.5m funding round led by VC Firm Kindred Capital and has now secured German engineering company Bosch as its first OEM customer. While the exact details of the deal are still under wraps, Kaafarani says the deal is indicative of the threats businesses are beginning to identify as the age of quantum computing approaches.

"Their hardware may be built to last, but right now, their security isn't," he says.

"If you're designing a car that's going to go on the roads in the next three years, if you're doing security by design, you should be thinking of the next security standards: not the standards that are valid now, but the standards that will be valid in the next five, 10, 15 years," he says.

"Future-proofing is an imperative, just as it is for the banks and agencies that hold so much of our sensitive data."

Be in the know about smart cities, AI, Internet of Things, VR, AR, robotics, drones, autonomous driving, and more of the coolest tech innovations. Delivered Wednesdays and Fridays

Original post:

The future of encryption: Getting ready for the quantum computer attack - TechRepublic

The US Is Building Quantum Internet That’ll Be Virtually Unhackable – IndianWeb2.com

The United States (US) Department of Energy (DOE) has unveiled a report that lays out a blueprint strategy for the development of a national quantum internet, an Internet based on quantum computing technology that when implemented will be virtually unhacabled.

Notably, a system that communicates using quantum mechanics represents one of the most important technological frontiers of the 21st century. One of the distinctive feature of quantum transmissions is that they are exceedingly difficult to eavesdrop (secretly or stealthily listening to the private conversation/communications) on as information passes between locations, making it (Quantum Internet) a virtually unhackable networks.

In February of this year, scientists from DOEs Argonne National Laboratory in Lemont, Illinois, and the University of Chicago created a 52-mile (83-kilometer) quantum loop in the Chicago suburbs, successfully establishing one of the longest land-based quantum networks in the nation. That network will soon be connected to DOEs Fermilab in Batavia, Illinois, establishing a three-node, 80-mile testbed.

The U.S. Department of Energy s 17 national laboratories will serve as the backbone of the coming quantum internet, which has initial government funding.

Scientists are also exploring how the quantum internet could expedite the exchange of vast amounts of data. If the components can be combined and scaled, society may be at the cusp of a breakthrough in data communication, according to the report.

Moreover, creating networks of ultra-sensitive quantum sensors could allow engineers to better monitor and predict earthquakesa longtime and elusive goalor to search for underground deposits of oil, gas, or minerals. Such sensors could also have applications in health care and imaging.

Read the original here:

The US Is Building Quantum Internet That'll Be Virtually Unhackable - IndianWeb2.com

Corporations Must Step Up to the Plate to Enhance the Security of Cloud Computing – Security Boulevard

Now that weve passed the midpoint in 2020, one thing in the cybersecurity world has become crystal clear: The need for better security within public clouds must be addressed by enterprises once and for all, and that entails cryptography.

No question, enterprises large and small have realized the benefits of rapidly deployable, reasonably priced and extremely scalable public computing infrastructure. According to Forbes, the global cloud computing market will reach $411 billion this year.

But what about the security? Is it up to snuff?

Not really, even though some public cloud purveyors offer some encryption as an option and sometimes by default. This step is hardly foolproof, however, and that should come as no surprise. After all, data in the cloud is stored with a third-party provider and accessed over the internet. This means visibility and control over that dataincluding its securityis limited.

Fact is, cloud service providers treat cloud security risks as a shared responsibility. The good news is that some cloud companies allow clients to encrypt their data before sending it to the cloud, and its becoming increasingly clear that thisor possibly the additional option of adopting a few other proven, state-of-the-art fixes for cloud securityis the preferred route for truly security-conscious enterprises.

That enhanced data encryption in the cloud makes sense began circulating roughly two-and-a-half years ago, when technology and cloud giant Accenture confirmed that it inadvertently left a gigantic store of private data access across four unsecured cloud servers. This exposed highly sensitive passwords and secret decryption keys that could have inflicted considerable damage on the company and its customers.

Since then, misconfigured cloud settings have caused multiple incidents of data exposures in the Amazon Web Services cloud. In addition, a misconfiguration error in Microsofts Azure cloud exposed 250 million technical support accounts. Meanwhile, MVISION Cloud, a unit of McAfee, analyzed the encryption controls offered by more than 12,000 providers and found yet more shortcomings. While 82percent of cloud service providers encrypt data in transit between the user and the cloud service, not even 10percent of cloud providers encrypt data once its stored, MVISION found.

According to CloudPassage, a software-as-a-service purveyor that provides security for private, public and hybrid clouds, one of the worst mistakes made by public cloud companies is having easily hacked administrative credentialsessentially the keys to the kingdom. As it turns out, attackers can execute a breach with a badly configured set of privileged credentialsa common occurrence, unfortunately, when a cloud company cuts corners in a rush to market.

Other mistakes among public crowd companies include exposed data assets, weak network access control and poor event logging, which impedes efforts to detect, contain and analyze compromises in the cloud.

On the bright side, there are companies today that help enterprises adopt cloud encryption. Oneborn out of research done at MITis cybersecurity company PreVeil, whose end-to-end encryption could redefine cloud-based cybersecurity in a way that doesnt interfere with workflows while still enabling popular cloud-based machine-learning applications.

Another company with a different approach to the same end goal is Zscaler, which offers a Secure Web Gateway in the cloud via software-as-a service. No hardware is required. Zscaler decentralizes cybersecurity protection, allowing data to flow back and forth from a public cloud rather than redirecting it to clients own physical data centers.

Another form of cryptography enhances the breadth of the science by offering fresh analytical capabilities as well as securityhomomorphic encryption (HE). HE is attracting more attention from select technology companies such as IBM, Microsoft and Google, and startups such as Enveil, and slowly growing. HE makes it possible to analyze or manipulate encrypted data without revealing the data to anyone, offering huge potential in areas with sensitive personal data such as in financial services or healthcareareas in which the privacy of a person is paramount.

The biggest barrier to widespread adoption of HE is that it is still very slow and so not yet practical for many applications. Nonetheless, company researchers are working diligently to speed up the process by decreasing the required computational overhead.

Microsoft, for example, has created SEAL, a set of encryption libraries that allow computations to be performed directly on encrypted data. SEAL is partnering with companies to build end-to-end encrypted data storage and computation services. Googleanother tech giant that has moved into the fieldlast year unveiled an open-source cryptographic tool similarly focused on analyzing data in its encrypted form with only the insights derived from the analysis visible, not the underlying data itself.

An even more futuristic development that cryptography-minded folks should be aware ofalthough in this case, in a blatantly negative senseis quantum computing, based on the principles of quantum physics.

At least a decade away, ultra-fast quantum computers could perform calculations exponentially faster than classic computersin the wrong hands potentially enabling the destruction of the encryption protecting their data. Fortunately, there is also some good news on this front. The National Institute of Standards and Technology is already pushing researchers to analyze potential problems in this post-quantum era. Meanwhile, IBM has already successfully demonstrated a quantum-proof encryption method it developed.

For now, here are six security tips for companies moving to public or even multi-cloud environments and concerned about cryptography and related security disciplines.

+ Get the basics right.Establish a strategy for multi-cloud encryption and the management of cryptography keys before expanding to more advanced crypto technologies.

+ Leverage encryption as part of your broader IT security efforts.Companies that dont have effective data classification and/or a prioritization program in place tend to struggle with data encryption. Data classification policies and tools facilitate the separation of valuable information that may be targeted from less valuable information.

+ Build in crypto agility.This refers to the capacity for an information security system to adopt an alternative to the original encryption method without significant change to system infrastructure. Be ready to replace or retire your deployed cryptography as needed.

+ Ensure that only authorized users can access data.This is critical to prevent tampering by anyone inside or outside the organization. Audit access controls regularly to ensure their validity.

+ Develop robust plans for business continuity and disaster recovery of crypto keys.Inventory keys and cryptographic libraries so you can recover your data alongside your protection mechanisms.

+ Make sure your cryptography is integrated intothe DevSecOps world.Ensure that DevOps teams choose crypto libraries that follow secure coding practices.

In the final analysis, encryption is tough stuff, but extremely important in the world of security. Companies that embrace it and incorporate it properly are taking an additional big step to protect their data and their reputation in a world inundated by embarrassing, hurtful and costly cyber-breaches.

Now that cloud computing has introduced encryption widely, security-minded companies are under growing pressure to keep the ball rolling and help move on to next steps.

Read the original here:

Corporations Must Step Up to the Plate to Enhance the Security of Cloud Computing - Security Boulevard

Quantum Computing In Aerospace and Defense Market Trend, Future Demand, Analysis by Top Leading Player Qxbranch LLC, IBM Corporation – Market…

QMI added another report to its archive, which presents an up-to-date analysis on Global Quantum computing in aerospace and defense Market. The global market is expected to see an increment in its sales and significant growth in its revenue. Some major companies operating in the market are D-Wave Systems Inc, Qxbranch LLC, IBM Corporation, Cambridge Quantum Computing Ltd, 1qb Information Technologies Inc., QC Ware Corp., Magiq Technologies Inc., Station Q-Microsoft Corporation, and Rigetti Computing.

Click Here to Get Sample of the Premium Report @

https://www.quincemarketinsights.com/request-sample-29723?utm_source=MRC&utm_medium=Arshad

In this study of Global Quantum computing in aerospace and defense Market, Quince Market Insights provides formidable forecasts up to the next 8-years. The global Quantum computing in aerospace and defense Market is projected to generate significant sales during the forecast period at a CAGR of XX per cent. The research report discloses current market dynamics in key geographic regions along with observation for the existing environment in the market and probable developments over the global Quantum computing in aerospace and defense Market forecast period.

Report analyzes the global Quantum computing in aerospace and defense Market for the period 20192028. This reports primary aim (Quantum computing in aerospace and defense Market) is to provide understandings on key market developments relevant to the Quantum computing in aerospace and defense Market that are slowly helping to transform the global industries.

The global report on Quantum computing in aerospace and defense Market begins with the summary for different categories and their share in the Quantum computing in aerospace and defense Market. It is followed by the global Quantum computing in aerospace and defense Markets market trends, dynamics, and overview, which includes analysis of market drivers, opportunities, and constraints which are likely to influence the global Quantum computing in aerospace and defense Markets growth. In addition, to understand the popularity of the Quantum computing in aerospace and defense Market segment, the attractiveness index and BPS analysis will be provided with detailed insights into the same, showing the attractiveness of the market based on factors such as CAGR and incremental opportunities.

Get TOC for overview of Premium report @https://www.quincemarketinsights.com/request-toc-29723?utm_source=MRC&utm_medium=Arshad

By Design, and global market for Quantum computing in aerospace and defense Market is further segmented. Based on the design, Quantum computing in aerospace and defense Market global market is segmented:

Market Segmentation:By Component: Hardware Software Services

By Application: Quantum Key Distribution (QKD) Quantum Cryptanalysis Quantum Sensing Naval

The next segment of the report highlights segmentation by region of the Quantum computing in aerospace and defense Market and gives the market forecast for 20192028. The report examines regional development as well as analyzes the factors affecting the regional Quantum computing in aerospace and defense Market. North America, Western Europe, Eastern Europe, Asia Pacific, Middle East, and Rest of the World are the major regions evaluated in this study.

To gauge the extent of the market in terms of value and size, consideration is given to the revenues generated by the major companies and their respective production capacity. The forecast presented here estimates the value-generated total revenue across the Quantum computing in aerospace and defense Market. To provide a precise forecast, we have initiated by sizing up the current market, which forms the basis on how the future development of the Quantum computing in aerospace and defense Market is predicted.

By Region:North Americao By Country (US, Canada, Mexico)o By Componento By Application

Western Europe:o By Country (Germany, UK, France, Spain, Italy, Rest of Western Europe)o By Componento By Application

Eastern Europe:o By Country (Russia, Turkey, Rest of Eastern Europe)o By Componento By Application

Asia Pacifico By Country (China, Japan, India, Australia, South Korea, Rest of Asia Pacific)o By Componento By Application

Middle East:o By Country (UAE, Qatar, Iran, Saudi Arabia, Rest of Middle East)o By Componento By Application

Rest of the Worldo By Region (South America, Africa)o By Componento By Application

Reasons To Buy This Report: Market size estimation of the quantum computing in aerospace and defense market on a regional and global basis Unique research design for market size estimation and forecast Profiling of major companies operating in the market with key developments Broad scope to cover all the possible segments helping every stakeholder in the market

Customization:We provide customization of the study to meet specific requirements: By Segment By Sub-segment By Region/Country

Contact:Quince Market InsightsAjay D. (Knowledge Partner)Office No- A109Pune, Maharashtra 411028Phone: US +1 208 405 2835 UK +44 144 439 0986 APAC +91 706 672 4848Email:[emailprotected]Web:www.quincemarketinsights.com

ABOUT US:QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Here is the original post:

Quantum Computing In Aerospace and Defense Market Trend, Future Demand, Analysis by Top Leading Player Qxbranch LLC, IBM Corporation - Market...